Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Other Non-Current Assets (2023 - 2025)

Historic Other Non-Current Assets for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $5.7 million.

  • Inhibrx Biosciences' Other Non-Current Assets fell 1451.13% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 1451.13%. This contributed to the annual value of $6.8 million for FY2024, which is 11589.76% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Other Non-Current Assets stood at $5.7 million, which was down 1451.13% from $6.8 million recorded in Q2 2025.
  • Inhibrx Biosciences' Other Non-Current Assets' 5-year high stood at $6.8 million during Q4 2024, with a 5-year trough of $3.2 million in Q4 2023.
  • Its 3-year average for Other Non-Current Assets is $6.1 million, with a median of $6.7 million in 2024.
  • As far as peak fluctuations go, Inhibrx Biosciences' Other Non-Current Assets skyrocketed by 11589.76% in 2024, and later crashed by 1451.13% in 2025.
  • Inhibrx Biosciences' Other Non-Current Assets (Quarter) stood at $3.2 million in 2023, then surged by 115.9% to $6.8 million in 2024, then dropped by 16.0% to $5.7 million in 2025.
  • Its Other Non-Current Assets stands at $5.7 million for Q3 2025, versus $6.8 million for Q2 2025 and $6.8 million for Q1 2025.